No connection

Search Results

KPTI vs LFCR

KPTI
Karyopharm Therapeutics Inc.
BEARISH
Price
$8.00
Market Cap
$180.3M
Sector
Healthcare
AI Confidence
90%
LFCR
Lifecore Biomedical, Inc.
BEARISH
Price
$4.75
Market Cap
$178.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
KPTI
--
LFCR
--
Forward P/E
KPTI
-1.83
LFCR
-5.72
P/B Ratio
KPTI
-0.5
LFCR
-12.53
P/S Ratio
KPTI
1.23
LFCR
1.38
EV/EBITDA
KPTI
-4.3
LFCR
42.48

Profitability

Gross Margin
KPTI
9.93%
LFCR
31.37%
Operating Margin
KPTI
-52.36%
LFCR
8.18%
Profit Margin
KPTI
-134.21%
LFCR
-23.78%
ROE
KPTI
--
LFCR
--
ROA
KPTI
-41.56%
LFCR
--

Growth

Revenue Growth
KPTI
11.6%
LFCR
--
Earnings Growth
KPTI
--
LFCR
--

Financial Health

Debt/Equity
KPTI
--
LFCR
4.15
Current Ratio
KPTI
1.12
LFCR
3.49
Quick Ratio
KPTI
0.98
LFCR
2.18

Dividends

Dividend Yield
KPTI
--
LFCR
--
Payout Ratio
KPTI
0.0%
LFCR
0.0%

AI Verdict

KPTI BEARISH

KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.

Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
LFCR BEARISH

LFCR presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation anchors like the Graham Number or Intrinsic Value. While the company shows strong short-term liquidity (Current Ratio 3.49) and positive Q/Q revenue growth, these are overshadowed by a critical negative book value (P/B -12.53) and excessive leverage (Debt/Equity 4.15). The technical trend is aggressively bearish (0/100), and the historical earnings track record is marked by extreme volatility and frequent misses.

Strengths
Strong short-term liquidity with a Current Ratio of 3.49
Positive Q/Q Revenue Growth of 25.92%
Positive Operating Margin of 8.18%
Risks
Negative Book Value (P/B -12.53) indicating significant equity erosion
High leverage with a Debt/Equity ratio of 4.15
Negative overall Profit Margin of -23.78%

Compare Another Pair

KPTI vs LFCR: Head-to-Head Comparison

This page compares Karyopharm Therapeutics Inc. (KPTI) and Lifecore Biomedical, Inc. (LFCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile